• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Hep C Guidance Update Quiz: Special Populations

News
Slideshow

The newest HCV guidance is out on special populations. Are you up to date? Take our short, 5-question quiz to find out. 

References: 1. Bourlière M, Gordon SC, Flamm SL, POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134-2146. 2. Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389-397.3. Schoenbachler BT, Smith BD, Seña AC, et al. Hepatitis C virus testing and linkage to care in North Carolina and South Carolina jails, 2012–2014. Public Health Rep. 2016;131:98-104. 

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
FluMist Intranasal Flu Vaccine Now Available for At-Home Delivery and Self-Administration

FluMist Intranasal Flu Vaccine Now Available for At-Home Delivery and Self-Administration

Sydney Jennings
August 18th 2025
Article

AstraZeneca launches FluMist Home, the first FDA-approved at-home flu vaccine service, allowing self- or caregiver administration of the intranasal influenza vaccine for the 2025–26 season.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings
May 7th 2025
Podcast

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Combating Vaccine Misinformation: Q&A With Amesh Adalja, MD

Combating Vaccine Misinformation: Q&A With Amesh Adalja, MD

Amesh Adalja, MD;Sydney Jennings
August 14th 2025
Article

Infectious disease expert Amesh Adalja, MD, discusses key vaccine policy changes, strategies to combat misinformation, and ways PCPs can boost vaccine confidence.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

FDA Accepts Priority Review of Gepotidacin for Oral Treatment of Uncomplicated Urogenital Gonorrhea / Image credit: ©MohamadFaisal/AdobeStock

FDA Accepts Gepotidacin for Priority Review for the Treatment of Uncomplicated Urogenital Gonorrhea

Sydney Jennings
August 11th 2025
Article

FDA accepts priority review of gepotidacin for uncomplicated urogenital gonorrhea, with phase 3 data showing non-inferiority to standard injectable therapy.

Nirsevimab Highly Effective in Preventing RSV-Related LRTD in Healthy Term Infants, Real-World Study Finds

Nirsevimab Highly Effective in Preventing RSV-Related LRTD in Healthy Term Infants, Real-World Study Finds

Sydney Jennings
July 25th 2025
Article

Nirsevimab lowered the risk of RSV-related illness by over 87% and hospitalizations by 98% in a new study.

© 2025 MJH Life Sciences

All rights reserved.